Business Context and Reporting Period
This Form 8-K is a current report filed by SELLAS Life Sciences Group, Inc. on March 11, 2024. The filing addresses a specific corporate governance event regarding the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance status.
Material Changes
The primary material event is the resolution of a listing deficiency:
- Regained Compliance: The Company received confirmation from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2) (Minimum Bid Price Requirement).
- Compliance Period: The Company maintained a minimum closing bid price of $1.00 per share for 10 consecutive business days between February 26, 2024, and March 8, 2024.
- Previous Status: On February 14, 2024, the Company had been notified of non-compliance due to the stock price falling below $1.00 for 30 consecutive business days.
- Grace Period: The Company was previously granted an 180-day grace period (until August 12, 2024) to regain compliance, which it has now satisfied early.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks. The only risk addressed is the prior risk of delisting due to low stock price, which has been mitigated by the successful restoration of compliance.
Investor Verification Checklist
- Verify the current trading price of SLS on Nasdaq to ensure it remains above the $1.00 threshold.
- Confirm that the Nasdaq listing status is active and no longer under review for delisting.
- Review the February 14, 2024, notification to understand the specific duration of the prior non-compliance.